IL1B and COVID-19: Several studies demonstrated that a prolonged pro-inflammatory state, which is characterized by the increase in inflammatory markers, such as IL-1β, IL-6, and TNF-α, is a distinctive feature of patients with long COVID-19 [12] since these inflammatory alterations have been shown to persist in some patients for several months after infection, leading to a condition clinically known as post-COVID-19 multisystem inflammatory syndrome (MIS) or a systemic inflammatory response (SIR) [13,14].